HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Investor Presentation
Further to the intimation dated October 14, 2022, we are submitting herewith the updated Investor Presentation.29-11-2022
29-11-2022
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Communication released to the Press with respect to commissioning of Solar Power Plant at Jagalur of Davanagere District, Karnataka. This was published in Newspapers on November 23/24, 2022.25-11-2022
HealthCare Global Enterprises Ltd - 539787 - Announcement As Per Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Disclosure of Related Party Transactions for the half year ended September 30, 2022.24-11-2022
HealthCare Global Enterprises Ltd - 539787 - Intimation Regarding Issue Of Duplicate Share Certificate Of Healthcare Global Enterprises Limited ('Company')
The Company, after complying with necessary formalities, has issued the letter of confirmation on November 22, 2022 in terms of SEBI Circular no. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 in place of share certificate lost by the said shareholder.23-11-2022
Buy Healthcare Global Enterprises; target of Rs 370: ICICI Direct
ICICI Direct is bullish on Healthcare Global Enterprises recommended buy rating on the stock with a target price of Rs 370 in its research report dated November 12, 2022.22-11-2022
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings Call held on November 11, 2022, with Analysts/Investors to discuss the Unaudited Financial Results of the quarter and half year ended September 30, 2022.17-11-2022
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement of Unaudited Financial Results of HealthCare Global Enterprises Limited ('the Company') for the quarter and half year ended September 30, 2022.12-11-2022
HealthCare Global Enterprises Ltd - 539787 - Earnings Call Held With Analysts/Investors To Discuss The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
Audio recording of the Earnings Call held on November 11, 2022, with Analysts/Investors to discuss the Unaudited Financial Results of the quarter and half year ended September 30, 2022, is made available on the website of the Company www.hcgoncology.com.11-11-2022
Q2FY23 Quarterly Result Announced for Healthcare Global Enterprises Ltd.
Healthcare Global Enterprises announced Q2FY23 results: Q2FY23: Revenue is Rs 4,200 million; up 19% YoY for Q2FY23 Adjusted EBITDA is Rs 810 million; up 28% YoY for Q2FY23 PAT is Rs 74 million; turns positive for Q2FY23 YoY H1FY23 Revenue Rs 8,281 million; up 23% YoY for H1FY23 Adjusted EBITDA is Rs 1,566 million, up 40% YoY for H1FY23 PAT is Rs 134 million; turns positive for H1FY23 YoY BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd, said, "HCG chain of dedicated cancer centres is consistently moving up the value chain of high-quality clinical care powered by high-end technology. Our Bangalore COE, which is one of India’s largest dedicated cancer care hospitals has recently launched India’s first Varian Ethos™ therapy, an Artificial Intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. It uses augmented intelligence, a convergence of people and artificial intelligence (AI) working together for better outcomes & higher success rates while maintaining the quality of life. This game-changing radiation therapy personalizes cancer care using adaptive intelligence based on the patient’s anatomy and the position of the tumour at the time of treatment. At HCG, we are equally focused and engaged in academics and research, we are very proud to announce that we have over 170 fellowship programs and different DNB programs in oncology, not only in Bangalore, but also in Tier 2, and Tier 3 cities. In research, for October, we have had nine new publications, and a significant number of them have been podium presentations, till date we have published more than 750 research papers. Our focus has been on Oncology in conjunction with local partners, which has helped us build a strong legacy as a World-class Oncology Treatment Center & Institution across India." Raj Gore, CEO HealthCare Global Enterprises Ltd, added, "We are happy to report another strong financial performance for the quarter that ended September 2022. Our consolidated revenue for Q2FY23 stood at Rs 4,200 mn, a growth of 19% on a YoY basis. Our focused efforts on cost rationalization coupled with strong revenue growth have resulted in a marginal expansion of 230 bps, leading to an adjusted EBITDA margin of 18.9% in H1FY23. Adjusted EBIDTA for H1FY23 stood at Rs 1,566 mn as compared to Rs 1,121 mn in H1FY22, a growth of 40% on YoY basis. As a result of consistent revenue growth & margin expansions, our reported PAT (excl. Exceptional items) has increased to Rs 74 Mn for Q2FY23 as compared to Rs 8.3 Mn in Q2FY22. While our mature centres continue to show higher than the market growth rate, the growth strategies implemented for the emerging centres have started showing promising results. Jaipur centre has more than doubled its revenue whereas Kolkata and Mumbai have grown by 40% & 30% respectively on a Y-o-Y basis in the current quarter Our differentiated and specialised cancer care along with strong brand positioning have enabled us to attain leadership position in 13 out of 18 locations where we are present. Going forward, we will continue to invest in HCG brand to make it the preferred choice for cancer patients across India. We are optimistic of improving our market share & strengthening our leadership position." Result PDF11-11-2022
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press on the Financial Results of the Company for the quarter and half year ended September 30, 2022.11-11-2022